Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04082338 · ClinicalTrials.gov registry record · NA
Chronic HBV Management for Asian American
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 382
- Enrollment target
NCT04082338 is a NA study that has completed, run by Temple University. The registered enrollment target is 382 participants.
The verdict
NCT04082338, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 382 participants
- Enrollment target
Study Summary
About 75% of liver cancers are attributed to chronic hepatitis B (CHB). An estimated 2.2 million individuals in the U.S. have CHB. Although Asian Americans make up 6% of total U.S. population, they account for over 58% of Americans with CHB. Prevalence rates of CHB range from 8% to 13% in Asian Americans vs 1% in Non-Hispanic whites (NHW). Asian Americans are 8-13 times more likely to develop liver cancer with 60% higher death rate than NHW. Regular monitoring of CHB is vital in preventing HCC. Research indicates that regular monitoring (e.g., every six months doctor visit; blood tests) combined with antiviral treatment when appropriate, is critical to reduce the risk of liver disease (including HCC). Unfortunately, treatment effectiveness diminishes if CHB patients do not adhere to long-term monitoring and treatment guidelines. Adherence among Asian Americans with CHB is low. Poor healthcare access and significant cultural barriers prevent long-term adherence to monitoring and optimal treatment, placing Asian Americans at disproportionately high risk for HCC and increased healthcare costs. Building on previous studies, the investigators will use a virtual patient navigation (VPN) toolkit system (a web/mobile application) to help CHB patients improving their liver disease management.
Interventions
- BEHAVIORAL VPN
- BEHAVIORAL TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2022-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04082338
The ClinicalTrials.gov registry entry for NCT04082338 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VPN is the first listed.
NCT04082338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04082338 about?
NCT04082338 is a clinical study titled "Chronic HBV Management for Asian American". About 75% of liver cancers are attributed to chronic hepatitis B (CHB). An estimated 2.2 million individuals in the U.S. have CHB. Although Asian Americans make up 6% of total U.S. population, they account for over 58% of Americans with CHB. Prevalence rates of CHB range from 8% to 13% in Asian Amer...
What is the current status of trial NCT04082338?
This trial is currently completed. It is a NA study. The enrollment target is 382 participants. The study started on 2019-04-01. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT04082338?
The interventions under investigation include: VPN (BEHAVIORAL), TM (BEHAVIORAL).
Who is sponsoring clinical trial NCT04082338?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.